Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
about
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisEtanercept for the treatment of rheumatoid arthritisAdverse effects of biologics: a network meta-analysis and Cochrane overviewEtanercept for the treatment of rheumatoid arthritisAnti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetySafety of extended treatment with anakinra in patients with rheumatoid arthritisPatterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort studyPhenotypic characteristics of human monocytes undergoing transendothelial migrationInterferon-beta for treatment of rheumatoid arthritis?Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritisTreatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritisAutoantibody profile in rheumatoid arthritis during long-term infliximab treatmentAnti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic miceDermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.Biologic interventions for fatigue in rheumatoid arthritisMacrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritisMonoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyInflammation induced loss of skeletal muscleA novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritisComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisA Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis PatientsrSj16, a recombinant protein of Schistosoma japonicum-derived molecule, reduces severity of the complete Freund's adjuvant-induced adjuvant arthritis in rats' modelTyrosine kinase inhibitors for the treatment of rheumatoid arthritisBiologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritisIncorporating data from various trial designs into a mixed treatment comparison model.[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data].Anti-inflammatory potential of alpha-linolenic acid mediated through selective COX inhibition: computational and experimental data.Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.Number needed to treat (NNT): implication in rheumatology clinical practice.Anakinra treatment of patients with rheumatoid arthritis.Radiography of rheumatoid arthritis in the time of increasing drug effectiveness.Current management of rheumatoid arthritis.Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
P2860
Q21134808-C60F25EE-3A03-41D3-BC7D-50D9C1A20EB1Q24185797-73A1AF3F-2140-4052-BEC8-15936C86B98AQ24202751-07EBF5BD-2F96-41CB-B5DF-E07169D401C8Q24234197-2387C5CA-40D3-4465-A7A6-30A49D15D50DQ24248004-ED886F70-A5D6-4983-8297-3901B05434EBQ24673716-D3D21BE2-8B3B-4A32-B8A9-1D4DDFD94012Q24675209-4759F518-1D6C-49BA-BCD7-C0838BDB8709Q24791246-5DE47050-6306-4E02-996A-A30B8996F558Q24793076-8D183EFA-AD7D-46C9-A14B-823E0B884B4AQ24793971-E9D22039-241C-463A-8E22-B23880034E1AQ24800647-8BD2219A-88BA-445B-B8ED-841CF32153B1Q24800661-8159B540-02A7-4645-A64C-2890C164459BQ24800888-FE64CD26-0B31-4004-82ED-10E90C02BE15Q24801075-8D877B4B-D4FB-4F0E-B2AC-1583F919303AQ24816844-E4BA7DE8-12BB-4374-8571-E7F4FA1951F8Q26471538-0A2ECE55-60A5-4C9F-B4F6-5498B208794DQ26750562-48736585-75F6-487B-B33C-4DE1B79E77A3Q26824970-7CF2B968-7F8A-4EC0-987B-5DC88CECBA74Q27694496-0D268292-4699-4BF8-85D8-62797173E558Q28083759-D9527378-641D-4372-9189-2ECEA314C8B2Q28250612-7E5F91DF-78B2-4EA8-8D76-CF750934E17DQ28547851-381E33EE-C127-4B41-AC17-3A213CB958BDQ28551075-98917D51-64B1-4B9F-A52B-2DDB70360612Q28564602-FB855A37-4800-40C3-8DC2-9968A22B0C73Q28674280-DC6FC7D9-B24C-4032-BE50-0579E4E8406FQ30235341-E66CADF4-15E6-48CA-93F6-D96A2D3593AAQ30351543-B4940395-762A-4766-A0AA-A132BE67DB94Q30576366-5521CE82-D5E8-40D4-AFCF-F191B91EC757Q30594247-8A692ABB-47EE-43D0-A143-01C71B1EBA50Q30699616-CA364018-1D95-41CE-A23F-8479E2A803A2Q30780014-80132D72-5D63-4759-98FB-68ABA5B579E6Q30863549-E531F187-C4A3-4164-8757-7493C3494029Q30896344-DAEF9F07-D43B-4633-B4FF-DD6B9F8A6FD5Q31089069-67E40A4B-88AA-4CBD-9CAF-1547F5899C1BQ31935385-38E74C9A-9124-4192-A054-5CFE4A8256D5Q32060900-A07EAFE6-0205-41C6-864C-45725527E5D1Q33245010-7AB10463-BA67-4C42-9281-82562492E0A8Q33311301-3916A5BF-8C3C-48C2-9C53-11B733541881Q33315300-CB94ECC4-87FC-44F4-9477-D8035D510B4DQ33328963-63768D71-AA2A-404C-BA84-5B4099C76665
P2860
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
@en
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
@nl
type
label
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
@en
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
@nl
prefLabel
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
@en
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
@nl
P2093
P1476
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
@en
P2093
Arkfeld DG
Baumgartner SW
Bulpitt KJ
Fleischmann RM
Garrison L
Horwitz DA
Keystone EC
P304
P356
10.7326/0003-4819-130-6-199903160-00004
P407
P577
1999-03-01T00:00:00Z